Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas. This is an ASCO Meeting Abstract from the 2026 ASCO ...

The decision follows the FDA’s review of an interim safety report for the first three patients treated in the trial.

CraniUS Therapeutics, a neurotechnology company developing a skull-embedded drug delivery platform designed to bypass the blood-brain barrier, today announced it has received an initial $1.1 million ...

Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma No significant financial ...

May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...

Alpha Tau Medical recently reported that its Alpha DaRT technology was used to safely treat a recurrent glioblastoma patient in Israel, marking the first intracranial application of its brain-specific ...

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

MB-101 received orphan drug designation for treating recurrent diffuse astrocytomas and glioblastoma, supporting rare disease treatments affecting fewer than 200,000 people in the U.S. Combining ...

B7-H3–directed CAR T-cell therapy showed safety and tolerability in recurrent glioblastoma patients, with no dose-limiting toxicities or severe adverse effects observed. The study achieved a 44% ...

A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity ...

For patients with recurrent glioblastoma, treatment with chimeric antigen receptor (CAR) T-cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, in ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...